---
title: CROs offering LC-MS Bioanalysis (Small Molecule) with Antibody-Drug Conjugate (ADC)
path: /explore/lc-ms-bioanalysis/antibody-drug-conjugate
companies_count: 13
---

# CROs offering LC-MS Bioanalysis (Small Molecule) with Antibody-Drug Conjugate (ADC)

13 published CROs match LC-MS Bioanalysis (Small Molecule) and Antibody-Drug Conjugate (ADC).

Locations in this set include United States, China, France, United Kingdom, Australia, and Canada.

Capabilities that show up most often in this set: Bioanalysis, Biomarker Assays, Ligand-Binding Bioanalysis (Large Molecule), Discovery Research, and Regulatory Affairs.

## Matching companies

- [Aliri Bioanalysis](/companies/aliribio)
  - Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
- [Amador Bioscience](/companies/amadorbioscience)
  - Amador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.
- [Aragen Life Sciences](/companies/aragen)
  - Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- [Celerion](/companies/celerion)
  - Global CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.
- [Certara](/companies/certara)
  - Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- [ChemPartner](/companies/chempartner)
  - Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- [Frontage Laboratories](/companies/frontagelab)
  - Global pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
- [KCAS Bio](/companies/kcasbio)
  - Leading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
- [Oncodesign Services](/companies/oncodesign-services)
  - Contract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
- [Pharma Inventor](/companies/pharmainventor)
  - Vancouver-based preclinical drug discovery CRO offering medicinal chemistry, custom synthesis, LC-MS/MS bioanalysis, high-throughput screening and ADC development for pharma and biotech teams. Lists 6,000+ sq ft of research facilities and in-house 400 MHz NMR.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [WuXi AppTec](/companies/wuxiapptec)
  - Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.